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Although aortic stenosis is a common condition associated with major morbidity, mortality, and health economic
costs, there are currently no medical interventions capable of delaying or halting its progression. Re-evaluation
of the underlying pathophysiology is therefore required so that novel therapeutic strategies can be developed.
Aortic stenosis is characterized by progressive aortic valve narrowing and secondary left ventricular hypertrophy.
Both processes are important because in combination they drive the development of symptoms and adverse
events that characterize the latter stages of the disease. In this review, the authors examine the pathophysiology
of aortic stenosis with respect to both the valve and the myocardium. In particular, the authors focus on the role
of inflammation, fibrosis, and calcification in progressive valve narrowing and then examine the development of
left ventricular hypertrophy, its subsequent decompensation, and the transition to heart failure. Finally the au-
thors discuss potential therapeutic strategies on the basis of similarities aortic stenosis shares with other patho-
logical conditions. (J Am Coll Cardiol 2012;60:1854–63) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.02.093Calcific aortic stenosis (AS) is the most common form of
valve disease in the Western world and represents a major
healthcare burden. Over the past decade, the number of
aortic valve replacements performed in the United States
has doubled, and with an increasingly elderly population,
the prevalence of AS is likely to double again in the next 20
years (1). However, the pathophysiology underlying AS
remains incompletely defined, and there are currently no
effective medical treatments capable of altering its course.
Furthermore, we lack reliable markers that can predict
disease progression, the future need for surgery, or mortal-
ity. There is therefore a pressing need to re-evaluate the
underlying pathophysiological processes involved.
AS is characterized by progressive narrowing of the aortic
valve that increases the pressure afterload on the left
ventricle. Myocytes enlarge and wall thickness increases in a
hypertrophic response that initially restores wall stress but
ultimately proves maladaptive. The rate at which patients
with AS move toward symptoms, adverse events, and the
need for surgery is determined both by the severity of the
valve narrowing and by the myocardial hypertrophic re-
sponse (2,3). Both processes are of clinical importance, and
although linked, they are under the influence of different
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2012, accepted February 14, 2012.pathological factors. In this review, we discuss each in turn,
focusing on the role of inflammation, fibrosis, and calcifi-
cation in the development of progressive valve narrowing
and then on the factors modulating the left ventricular
hypertrophic response, its decompensation, and the transi-
tion to heart failure. Finally, we review the similarities AS
shares with other pathological conditions, with the aim of
highlighting potential targets for novel therapeutic
interventions.
Valve Narrowing
Anatomy of the normal valve. Normal aortic valves are
made up of 3 cusps (Fig. 1), the arrangement of which
results in even distribution of mechanical stress to the valve
ring and the aorta (4). Each cusp is 1 mm thick and
appears smooth, thin, and opalescent, with very few cells.
They are composed of 4 clearly defined tissue layers: the
endothelium, fibrosa, spongiosa, and ventricularis (Fig. 1).
At their base, the valve leaflets are attached to a dense
collagenous network, called the annulus, which facilitates
their attachment to the aortic root and the dissipation of
mechanical force.
Pathology. In calcific AS, the valve cusps become progres-
sively thickened, fibrosed, and calcified. This results in
increased valve stiffness, reduced cusp excursion, and pro-
gressive valve orifice narrowing that contrasts with the cusp
fusion seen with rheumatic heart disease. Historically,
calcific AS has been attributed to prolonged “wear and tear”
and age-associated valvular degeneration. However, recent
evidence suggests that it is instead the result of active
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November 6, 2012:1854–63 Calcific Aortic Stenosisinflammatory processes involving biochemical, humoral,
and genetic factors (Fig. 2).
MECHANICAL STRESS AND ENDOTHELIAL DAMAGE. The
early stages of AS are in many ways similar to those of
atherosclerosis (Table 1). As with atherosclerosis, the initi-
ating event is believed to be endothelial damage resulting
from increased mechanical stress and reduced shear stress.
This results in a characteristic distribution of lesions within
the stenotic valve. Shear stress is highest in the cusps
adjacent to the coronary ostia because of the influence of
coronary artery flow. Consequently, the noncoronary cusp
has lower shear stress and is most frequently involved in AS.
Mechanical tissue stress is highest around the flexion areas
of the cusps near their attachment to the aortic root, and
50% of lesions can also be observed in this region (5).
However, the bicuspid aortic valve perhaps best illustrates
the role of mechanical stress in the pathogenesis of AS. This
common congenital abnormality is characterized by a
2-cusp structure that results in a less efficient distribution
and concentration of mechanical forces within the valve
such that AS develops almost invariably and on average 2
decades earlier than in patients with tricuspid valves (6).
INFLAMMATION. Endothelial injury or disruption may al-
ow lipids to penetrate the valvular endothelium and accu-
ulate in areas of inflammation (7,8). The lipoproteins
mplicated in atherogenesis, including low-density lipopro-
ein and lipoprotein(a), are present in early aortic valve
esions (7) and undergo oxidative modification (8). These
xidized lipoproteins are highly cytotoxic and capable of
timulating intense inflammatory activity and subsequent
ineralization (Fig. 2) (9).
A combination of endothelial damage and lipid deposi-
ion triggers inflammation within the valve. The expression
f adhesion molecules allows infiltration of the endothelial
ayer by monocytes that differentiate into macrophages (10)
nd T cells that release proinflammatory cytokines, includ-
ng transforming growth factor–beta-1 (11), tumor necrosis
actor–alpha, and interleukin-1–beta (12). These inflamma-
ory cells and cytokines ultimately help stimulate and
stablish the subsequent fibrotic and calcific processes that
rive increasing valve stiffness (Fig. 2).
An inflammatory basis for AS is supported by studies
emonstrating increased systemic C-reactive protein con-
entrations in patients with AS (13) and increased temper-
ture in stenotic aortic valve cusps (14) and more recently by
oninvasive imaging studies using combined positron emis-
ion tomography and computed tomography. Fluorine-18
uorodeoxyglucose is a positron emission tomographic li-
and that serves as a marker of macrophage activity and has
ecome an established means of measuring inflammation in
ortic and carotid atheroma (15). More recently, 18F fluo-
rodeoxyglucose levels have been shown to be increased in
patients with AS compared with controls, displaying a pro-
gressive rise in activity with increasing valve severity (16).ANGIONEOGENESIS AND VALVE
HEMORRHAGE. Histological stud-
ies have suggested that these inflam-
matory processes are sustained by
angioneogenesis in the valve. Thin
neovessels are commonly observed
in regions of intense inflammation
surrounding calcific deposits and
demonstrate a positive correlation
with T-lymphocyte density. Fur-
thermore, both intercellular adhe-
sion molecule-1 and vascular cell
adhesion molecule-1 expression is
increased in these vessels, suggesting that they act as an important
portal of entry for inflammatory cells (17). Hemorrhage related to
these vessels also appears to be important, being present in 78% of
patients with severe AS and associated with neovascularization,
Figure 1 Normal Structure of the Trileaflet Aortic Valve
(A) The valve cusps have a 4-layered structure. On the aortic and ventricular
aspects of the valve is the endothelium, which is continuous with that of the
aortic endothelium and left ventricular endocardium. Moving toward the ventric-
ular aspect of the valve is the fibrosa, which consists of fibroblasts and colla-
gen fibers. The spongiosa is predominantly found at the base of the leaflets. It
is a layer of loose connective tissue containing mucopolysaccharides, mesen-
chymal cells, and fibroblasts, whose function is to resist compressive forces
within the cusps. Finally, the ventricularis is found on the ventricular aspect of
the valve and contains elastin fibers orientated perpendicularly to the collagen.
(B) Short-axis views of the aortic valve. Aortic aspect of the valve displays the
concentric arrangement of collagen fibers in the fibrosa layer of the valve. Ven-
tricular aspect showing the radial arrangement of elastin fibers in the
ventricularis.
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
AS  aortic stenosis
OPG  osteoprotegerin
RANK  receptor activator
of nuclear factor kappa B
RANKL  receptor
activator of nuclear factor
kappa B ligand
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(Fig. 2) (18).
FIBROSIS. The stenotic aortic valve is characterized by exten-
sive thickening due to the accumulation of fibrous tissue and
remodeling of the extracellular matrix. In all 3 layers of the
valve, abundant fibroblast-like cells are found. They contain
vimentin and are commonly referred to as valve interstitial
Figure 2 Summary of the Pathological Processes Occurring Wi
Mechanical stress results in endothelial damage that allows infiltration of lipid and infl
within these lesions and the secretion of proinflammatory and profibrotic cytokines. Th
collagen under the influence of angiotensin. In combination with the action of matrix m
nized fibrous tissue accumulates within the valve. This leads to thickening and increas
eration. Microcalcification begins early in the disease, driven by microvesicle secretion
the differentiation of myofibroblasts into osteoblasts. This occurs under the influence
nuclear factor kappa B (RANK)/RANK ligand (RANKL), Runx 2-cbfal 2, Wnt3-Lrp5-b cat
of the valve as part of a highly regulated process akin to skeletal bone formation, with
(Alk P), and bone morphogenic protein (BMP)-2. With time, maturation of valvular calci
and hemopoeitic tissue can all be observed within the valve. These pathogenic proces
regions of inflammation surrounding calcific deposits. Hemorrhage in relation to these
ing disease progression. IL-1  interleukin-1–beta; LDL  low-density lipoprotein; TG
Comparisons Between the Pathological Processes Underlying AortiTable 1 Comparisons Between the Pathological Processes Und
Aortic Stenosis
Initiating event Increased mechanical stress and reduced shear s
endothelial damage
Predominant cell types Macrophages and T helper cells
Valve interstitial cells
Myofibroblasts
Osteoblasts
Early pathology Oxidized lipid deposition, inflammation
Later pathology Calcification and fibrosis predominate
Neovascularization and hemorrhage
Disease progression Fibrosis, calcification, and hemorrhage
Mechanism of adverse events Progressive valve rigidity due to calcification and
Decompensation of the hypertrophic responsecells. A subpopulation of these cells become activated by the
inflammatory activity within the valve and differentiate into
myofibroblasts, which are believed to be responsible for the
accelerated fibrosis observed in this condition (19). In addition,
matrix metalloproteinases are secreted by myofibroblasts and
inflammatory cells and have an important and complex role in
the restructuring of the valve leaflet matrix (Fig. 2) (12,20).
he Valve During Aortic Stenosis
tory cells into the valve. Lipid oxidization further increases inflammatory activity
r drives the differentiation of fibroblasts into myofibroblasts that secrete increased
proteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), disorga-
ffness of the valve and in the latter stages the development of myxoid fibrous degen-
crophages. However, calcification accelerates in a proportion of patients because of
ral procalcific pathways, including osteoprotegerin (OPG)/receptor activator of
nd tumor necrosis factor (TNF)-. Osteoblasts subsequently coordinate calcification
ssion of many of the same mediators, such as osteocalcin, alkaline phosphatase
occurs so that by the end stages of the disease, lamellar bone, microfractures,
re sustained by angioneogenesis, with new vessels localizing, in particular, to
ls has also been demonstrated in severe disease and may have a role in accelerat-
ansforming growth factor.
nosis and Atherosclerosisng Aortic Stenosis and Atherosclerosis
Atherosclerosis
ausing Increased mechanical stress and reduced shear stress causing
endothelial damage
Macrophages and T helper cells
Foam cells
Vascular smooth muscle cells
Oxidized lipid deposition, inflammation, foam cells
Lipid deposition and pools, inflammation, and calcification
Neovascularization and hemorrhage
Lipid deposition and pools, inflammation, plaque rupture, and thrombosis
s Plaque rupture due to lipid-rich pool, inflammatory infiltrate,
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November 6, 2012:1854–63 Calcific Aortic StenosisThe renin-angiotensin system is thought to modify this
fibrotic process. Tissue angiotensin-converting enzyme
(ACE) and angiotensin II are both up-regulated in stenotic
aortic valves, and angiotensin receptors have been identified
on valve myofibroblasts (21).
CALCIFICATION. Valve calcification plays a key role in the
development of AS and can be quantified using computed
tomography. The degree of valvular calcification correlates
with valve severity (22), disease progression (23), and the
development of symptoms and adverse events (24). More-
over, disorders of mineral metabolism, including Paget
disease (25), osteoporosis (26), vitamin D polymorphisms
(27), and hemodialysis (28), are all associated with an
increased prevalence of AS.
Although other processes predominate, microscopic areas
of calcification can be observed in the early stages of aortic
sclerosis, co-localizing to areas of lipid deposition. In
one-sixth of patients with sclerosis, the calcification process
accelerates, hemodynamic obstruction ensues, and the valve
becomes stenotic (29). This progression is thought to be
driven by the differentiation of myofibroblasts into osteo-
blasts under the influence of the Wnt3-Lrp5- catenin
signaling pathway (30), the osteoprotegerin (OPG)/receptor
activator of nuclear factor kappa B (RANK)/RANK ligand
(RANKL) pathway (31) and Runx-2/NOTCH-1 signaling
(Fig. 2) (32). Osteoblasts subsequently coordinate calcifica-
tion as part of a highly regulated process, akin to new bone
formation (33), with the local production of many factors
more commonly associated with skeletal bone metabolism,
including osteopontin, osteocalcin, bone sialoprotein, and bone
morphogenic protein 2 (33–36). In addition, serum concen-
trations of fetuin A, an inhibitor of calcification, are reduced in
patients with AS (37).
In the early stages of AS, calcification is composed of
nodules containing hydroxyapatite deposited on a bonelike
matrix of collagen, osteopontin, and other bone matrix
proteins (34,35,38). Remodeling of this calcification occurs
as AS progresses until by the later stages of disease, lamellar
bone, microfractures, and hemopoeitic tissue can all be
identified within the valve (35). Combined positron emis-
sion tomographic and computed tomographic imaging has
confirmed the pathogenic role of calcification in AS using
18F sodium fluoride (16). This tracer exchanges with hy-
droxyl groups on hydroxyapatite crystal and is believed to
detect areas of developing or remodeling calcification. Up-
take of 18F sodium fluoride is increased within stenotic and
sclerotic aortic valves compared with control subjects, dis-
playing a progressive rise in activity with increasing disease
severity. This rise accelerates and is disproportionate to that
displayed by 18F fluorodeoxyglucose, with 97% of patients
with moderate AS and all patients with severe disease
displaying increased 18F sodium fluoride activity (16). In our
opinion, this tracer holds considerable potential as a bio-
marker of disease activity, and the extent of its uptake adds cfurther support to calcification as the key process in the
pathogenesis of aortic valve narrowing.
Left Ventricular Hypertrophy
AS causes an increase in pressure afterload and ventricular
wall stress that stimulates hypertrophy of the left ventricular
myocardium. Myocytes enlarge and wall thickness increases
in a response that initially restores wall stress and preserves
left ventricular function (39,40). However, evidence is
accumulating that increasing levels of hypertrophy may in
fact be maladaptive. The landmark Framingham studies
first linked increasing hypertrophy with the progression to
heart failure (41), and left ventricular hypertrophy is now
considered a marker of an adverse prognosis across a
number of cardiac conditions (42,43). In AS, patients
display a marked variation in the magnitude of their
hypertrophic response. This has recently been demonstrated
to be of prognostic importance (3) and might explain the
marked heterogeneity between symptom onset and the
severity of valve narrowing that is observed.
Variation in the degree of left ventricular hypertrophy. It
is perhaps surprising that in patients with AS, the degree of
left ventricular hypertrophy is only weakly related to the
severity of valve obstruction (44–46). This was first estab-
lished with echocardiography but has recently been con-
firmed using cardiac magnetic resonance, with which no
correlation between peak aortic valve velocity and indexed
left ventricular mass was observed (47). Instead, the mag-
nitude of the hypertrophic response appears to be more
closely associated with other factors, such as advanced age,
male sex, and obesity (44,48,49). Genetic factors modulate
the degree of hypertrophy in response to a wide range of
physiological and pathological triggers (50,51), and in AS,
polymorphisms of the ACE 1/D gene have been associated
with variation in left ventricular mass (49).
Other contributors to an increased afterload frequently
coexist in patients with AS and are likely to modulate the
hypertrophic response. Hypertension is common in this
patient group, and an analysis of participants in the SEAS
(Simvastatin and Ezetimibe in Aortic Stenosis) trial showed
that coexistent hypertension was associated with increased
left ventricular mass and a higher prevalence of hypertrophy
(52). Increased arterial stiffness is also frequently observed
because of a combination of advanced age, coexistent
atherosclerosis, diabetes, and high blood pressure. This
results in increased afterload and contributes to the devel-
opment of left ventricular dysfunction in AS (53). On this
basis, a global measure of afterload, ZVA, has been proposed
hat is derived from both the mean valve gradient and the
ystemic arterial compliance. This variable predicts an ad-
erse prognosis among patients with moderate and severe
S and has been proposed as a means of improving risk
tratification and clinical decision making (54).
The variation in the hypertrophic response has importantlinical consequences. In a study of 218 patients with
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Calcific Aortic Stenosis November 6, 2012:1854–63asymptomatic severe disease, Cioffi et al. (3) demonstrated
that subjects with inappropriately high left ventricular
mass had increased mortality compared with patients
with comparable valve narrowing but more moderate
hypertrophy. The mechanism for this adverse prognosis
is likely to relate to premature decompensation of the
hypertrophic process.
From hypertrophy to heart failure. The transition from
hypertrophy to heart failure marks the tipping point at
which the left ventricle fails in the face of an increased
pressure afterload and is no longer able to maintain forward
flow through the valve. This heralds the onset of symptoms,
adverse events, and a poor prognosis. Hein et al. (55)
established that this key progression is associated with in-
creased myocyte apoptosis and fibrosis and postulated that
these two processes were responsible for the transition (Fig. 3).
MYOCYTE APOPTOSIS. The rate of apoptosis in the hyper-
rophied myocardium has been estimated at 5% to 10% of
yocytes per year (56). Apoptosis is usually balanced by
yocyte regeneration, but in hypertrophy there appears to
e a net loss of cells. Increased apoptotic rates may simply be
response to the direct mechanical forces associated with
ncreased afterload (57,58). However, angiotensin II has
lso been implicated, and angiotensin receptor blockers
educe apoptosis in patients with hypertension, even at
oses that do not reduce blood pressure (59,60). Ischemia
ay also be important. In AS, myocardial oxygen demand is
ncreased by a combination of the elevated myocardial mass
nd increased afterload. In contrast to physiological hyper-
rophy, the density of the coronary capillary network does
ot expand sufficiently to meet this demand and coronary
ow reserve is impaired (Fig. 3) (61). Galiuto et al. (62)
emonstrated impaired myocardial perfusion in patients
ith severe AS and normal coronary arteries and that this
as associated with increased cardiomyocyte apoptosis.
FIBROSIS. Histopathological studies have confirmed fibrosis
to be an integral part of the hypertrophic process (63,64).
Myofibroblasts infiltrate the myocardium and secrete extra-
cellular matrix proteins, including collagen types I and III
(65). Areas of fibrosis are observed to co-localize with areas
of myocyte apoptosis (66), and it has been suggested that
fibrosis occurs as a form of scarring after myocyte death and
injury. As with fibrosis in the valve, the renin-angiotensin
system, transforming growth factor–beta, and an imbalance
in matrix metalloproteinase and tissue inhibitor of matrix
metalloproteinase activity have all been implicated in this
process (Fig. 3) (67,68).
Cardiac magnetic resonance imaging using late gadolin-
ium enhancement allows the noninvasive visualization of
replacement fibrosis within the myocardium. A midwall
pattern of fibrosis has been observed in the myocardium of
up to 38% of patients with moderate or severe AS and has
been associated with a more advanced hypertrophic re-
sponse (69). Importantly, there is also an 8-fold increase in
mortality associated with midwall fibrosis (69). This tech-nique can therefore serve as a prognostic marker and a
means of detecting decompensation of the hypertrophic
response before heart failure intervenes (Fig. 3). The mech-
anism for the adverse prognosis, however, remains unclear.
In part, it is likely to reflect the systolic and diastolic
impairment associated with myocardial apoptosis and fibro-
sis, the former leading to a reduction in the ventricular
contractile mass and the latter resulting in increased ven-
tricular stiffness (55,70,71). However, arrhythmia may also
contribute (72). Late gadolinium enhancement has been
associated with ventricular arrhythmia in other cardiac
conditions (73), and fibrosis predisposes to arrhythmia by
impairing electrical conduction, encouraging the develop-
ment of re-entry circuits and increasing ventricular refrac-
Figure 3 The Development and Subsequent Decompensation
of LV Hypertrophy in Response to Aortic Stenosis
Aortic valve narrowing imposes increased afterload and wall stress on the left
ventricle. This stimulates a hypertrophic response, which initially restores wall
stress and maintains cardiac performance. However, this process ultimately
becomes decompensated. Myocyte apoptosis is triggered by a combination of
myocardial ischemia, direct mechanical forces, and the actions of angiotensin.
This triggers a fibrotic response in the myocardium under the influence of profi-
brotic mediators such as angiotensin and transforming growth factor (TGF)–
beta, which can be visualized using the late gadolinium enhancement
technique (red arrows show regions of midwall fibrosis on short-axis views of
the left ventricle). Increasing myocardial fibrosis leads to progressive systolic
and diastolic impairment and the progression to heart failure. Symptoms and
adverse events ensue perhaps in part because of an increased tendency to
arrhythmia. LV  left ventricular.toriness and myocyte excitability (74,75). Importantly, pa-
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after aortic valve replacement, and this has been related to
advanced left ventricular hypertrophy (76,77). Although
potentially interesting, this hypothesis requires further
work, as the contribution of malignant arrhythmia to
sudden cardiac death in AS is incompletely defined.
The late gadolinium enhancement technique is limited by
the fact that it identifies only regional differences in replace-
ment myocardial fibrosis. It will therefore miss diffuse
interstitial fibrosis, which is evenly distributed throughout
the myocardium and the predominant fibrotic response in
AS. However, cardiac magnetic resonance T1 mapping
systems have recently been developed that enable the
detection and quantification of this form of fibrosis. These
are likely to become the preferred method of assessment in
AS, having already undergone histological validation and
been shown to correlate with symptomatic status (78,79).
Clinical Correlates and
Future Treatment Strategies
To date, there are no effective medical treatments for AS.
These are urgently required, because they might eliminate
the need for invasive cardiac surgery in patients who are
often elderly and not ideally suited to a major operation.
Similarities exist between the pathogenesis of AS and
several other common medical conditions that provide a
rationale for possible novel therapeutic strategies (Fig. 4).
Figure 4 Similarities Between Aortic Stenosis and Other Medic
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; LV
of nuclear factor kappa B; RANKL  receptor activator of nuclear factor kappaInflammation, atherosclerosis, and statin therapy. Ath-
erosclerosis and AS share many common risk factors, and
are both characterized by endothelial damage, lipid deposi-
tion, angioneogenesis, and inflammation (Table 1). Statin
therapy slows the progression of coronary and carotid
atheroma and reduces major adverse cardiac events, leading
to the hypothesis that statins might also delay progressive
valve narrowing in AS (Fig. 4). However, this strategy has
proved disappointing, with 3 major prospective randomized
controlled trials failing to demonstrate any impact on disease
progression or clinical outcomes (80–82). These results prob-
ably reflect important pathophysiological differences between
the development and progression of AS and atherosclerosis
(Table 1). In atherosclerosis, inflammation and lipid deposition
are key components in both the development of arterial plaque
and its stability. Adverse events are predominantly related to
plaque rupture, and much of the benefit from statin therapy is
due to plaque stabilization and a thickening of the fibrous cap.
In contrast, in AS, adverse events are related to progressive
narrowing of the aortic valve. This is predominantly driven by
increasing calcification, a process that statins have consistently
failed to affect, even in the context of coronary atherosclerosis
(83–85).
It is our opinion that the early stages of AS are established
in a manner akin to atherosclerosis. However, once osteoblast
activity has been established in the valve, progressive calcifica-
tion predominates in a manner that is quite distinct from the
nditions and Potential Therapeutic Strategies
ft ventricular hypertrophy; OPG  osteoprotegerin; RANK  receptor activator
nd.al Co
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Calcific Aortic Stenosis November 6, 2012:1854–63pathogenesis of atherosclerosis. Consequently, disease progres-
sion in these patients is more likely to be regulated by the
mediators of calcium homeostasis than atherogenesis. In sup-
port of this concept, although atherosclerotic risk factors and
serum C-reactive protein concentrations predict the develop-
ment of AS, they do not predict subsequent disease progression
(86,87). Rather, this is best predicted by the degree of valvular
calcification at baseline (87).
Fibrosis, hypertension, and antifibrotic medication. In a
similar fashion to AS, hypertension is characterized by an
increased pressure afterload and left ventricular hypertrophy
under the influence of the renin-angiotensin-aldosterone sys-
tem. It is therefore encouraging that in patients with hyper-
tension, ACE inhibitors and angiotensin receptor blockers
reduce left ventricular hypertrophy beyond their effects on
blood pressure, with favorable effects on myocardial fibrosis,
diastolic function, and clinical outcomes (88,89).
The impact of ACE inhibitors and angiotensin receptor
blockers in AS is less well studied. Beneficial effects with
respect to hypertrophy have been observed in experimental
animal models (90–92), whereas results on valve narrowing
have been conflicting in 2 retrospective human studies
(93,94). More encouragingly, a reduction in mortality and
cardiovascular events was observed in a recent observational
study in patients with AS maintained on ACE inhibitors
(95). Despite prior concerns, published research suggests
that ACE inhibitors are well tolerated even in patients with
severe AS (96,97), and large-scale prospective randomized
controlled trials of this therapeutic strategy are now required
(98) (Fig. 4).
alcification and osteoporosis. Patients with osteoporosis
have an increased incidence of AS and display more rapid
rates of disease progression (26,99). Both conditions are
characterized by abnormalities in calcium metabolism and
are governed by common systemic regulatory systems,
which coordinate calcium homeostasis via the action of
osteoblasts and osteoclasts.
In particular, the OPG/RANK/RANKL axis appears to
have a central role in both conditions. OPG is a decoy
receptor for RANKL: a potent stimulator of osteoclast
differentiation and bone resorption (100). Increased expres-
sion of RANKL and reduced levels of OPG have been
observed in osteoporosis and have led to the development
the anti-RANKL monoclonal antibody denosumab as a
highly efficacious and well-tolerated osteoporosis treatment
(101). Similarly, increased RANKL and reduced OPG have
also been observed within stenotic aortic valves (31) (Fig. 2),
while mice with targeted inactivation of OPG develop
extensive vascular calcification alongside high-turnover os-
teoporosis (102).
Calcification is the critical process in determining the
progression of aortic valve stenosis and is therefore likely to
be a crucial treatment target. The overlap in pathophysiol-
ogy between AS and osteoporosis provides a strong rationale
for drugs, such as bisphosphonates, that are already known
to have beneficial effects with regard to vascular calcification(103). These agents have also been shown to reduce valvular
calcification in patients with renal failure and bioprosthetic
valves (103,104) and appeared to slow disease progression in
a small observational study of patients being treated for
osteoporosis (26). Given the central regulatory role of the
OPG/RANK/RANKL system, novel medications such as
denosumab also hold promise, and there is therefore a
strong rationale for randomized controlled trials of these
treatments in AS.
Conclusions
AS is a common condition associated with major morbidity
and mortality, due to both progressive valve narrowing and
consequent left ventricular hypertrophy. However, to date,
there are no effective medical therapies that can halt or delay
disease progression. Calcification is believed to be the
predominant mechanism by which progressive valve nar-
rowing occurs, while fibrosis appears to drive decompensa-
tion of the hypertrophic myocardial response. We believe
that osteoporotic and antifibrotic interventions hold consid-
erable promise as future treatment strategies and that efforts
should now be focused on their development.
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